Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients

Liver Transpl. 2024 Feb 1;30(2):226-228. doi: 10.1097/LVT.0000000000000233. Epub 2023 Aug 3.

Authors

Seth H Richardson¹, Gunther Wong², Erica Garner³, Manhal Izzy⁴, Gitanjali Srivastava^{1

2

3}

Affiliations

¹ Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
² Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
³ Vanderbilt Weight Loss Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁴ Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

PMID: 37530854
DOI: 10.1097/LVT.0000000000000233

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Diabetes Mellitus, Type 2*
Glucagon-Like Peptide 1 / therapeutic use
Humans
Hypoglycemic Agents / therapeutic use
Liver Transplantation* / adverse effects

Substances

Glucagon-Like Peptide 1
Hypoglycemic Agents

Grants and funding

UL1 TR002243/TR/NCATS NIH HHS/United States